Open AccessNano-drug delivery system for the treatment of acute myelogenous leukemia
Author(s) -
Shaoqi Zhang,
Jun Sun
Publication year - 2022
Publication title -
zhejiang daxue xuebao. yixue ban
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.14
H-Index - 13
ISSN - 1008-9292
DOI - 10.3724/zdxbyxb-2022-0084
Subject(s) - nanocarriers , drug delivery , drug , pharmacology , bioavailability , nanomedicine , pharmacokinetics , biocompatibility , liposome , targeted drug delivery , pharmacodynamics , nanotechnology , medicine , nanoparticle , materials science , metallurgy
Administration of therapeutic drugs has been the core strategy for acute myelogenous leukemia (AML), but it is generally limited by its low bioavailability, toxic side effects and intravenous administration. The nano-drug delivery system significantly improves the anti-AML activity through targeted optimization of the drug delivery system. Organic nanocarriers include polymers, liposomes, nanoemulsion, nanomicelle and proteins, which have the advantages of high loading capacity, biocompatibility and functionalization. Inorganic nanocarriers include gold nanoparticles, silicon nanoparticles, iron nanoparticles and other inorganic nanoparticles, which exhibit diverse physical and chemical properties, and have a wide range of biomedical applications including drug carriers. Both organic and inorganic nanocarriers exhibit the potential to alter the pharmacokinetics and pharmacodynamics of drugs. This article reviews the recent progress of nanocarriers as drug delivery system in clinical applications of AML treatment.